CL2024001560A1 - Radioligandos escindibles para dirigirse a receptores de la superficie celular y usos de los mismos. - Google Patents
Radioligandos escindibles para dirigirse a receptores de la superficie celular y usos de los mismos.Info
- Publication number
- CL2024001560A1 CL2024001560A1 CL2024001560A CL2024001560A CL2024001560A1 CL 2024001560 A1 CL2024001560 A1 CL 2024001560A1 CL 2024001560 A CL2024001560 A CL 2024001560A CL 2024001560 A CL2024001560 A CL 2024001560A CL 2024001560 A1 CL2024001560 A1 CL 2024001560A1
- Authority
- CL
- Chile
- Prior art keywords
- compound
- solvate
- cleavable
- pharmaceutically acceptable
- radioligands
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/081—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the protein being an albumin, e.g. human serum albumin [HSA], bovine serum albumin [BSA], ovalbumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163283361P | 2021-11-26 | 2021-11-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024001560A1 true CL2024001560A1 (es) | 2025-03-28 |
Family
ID=86540347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024001560A CL2024001560A1 (es) | 2021-11-26 | 2024-05-23 | Radioligandos escindibles para dirigirse a receptores de la superficie celular y usos de los mismos. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12214059B2 (https=) |
| EP (1) | EP4436979A1 (https=) |
| JP (1) | JP2024542592A (https=) |
| KR (1) | KR20240121775A (https=) |
| CN (1) | CN118451091A (https=) |
| AU (1) | AU2022397307A1 (https=) |
| CA (1) | CA3238734A1 (https=) |
| CL (1) | CL2024001560A1 (https=) |
| MX (1) | MX2024005950A (https=) |
| WO (1) | WO2023097038A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018204872A2 (en) * | 2017-05-05 | 2018-11-08 | Fusion Pharmaceuticals Inc. | Igf-1r monoclonal antibodies and uses thereof |
| AU2022397307A1 (en) | 2021-11-26 | 2024-06-06 | Full-Life Technologies Uk Limited | Cleavable radioligands for targeting cell surface receptors and uses thereof |
| WO2024126687A1 (en) * | 2022-12-16 | 2024-06-20 | Silence Therapeutics Gmbh | Nucleic acids conjugated to an albumin binding moiety |
| CN121219017A (zh) * | 2023-05-31 | 2025-12-26 | 辐联科技香港有限公司 | 缀合物及其用途 |
| AU2024282578A1 (en) * | 2023-05-31 | 2025-12-04 | Full-Life Technologies Uk Limited | Radioligands for targeting cell surface receptors and uses thereof |
| TW202540073A (zh) * | 2023-11-30 | 2025-10-16 | 大陸商輻聯科技香港有限公司 | 靶向ｓｓｔｒ受體的放射性化合物及其用途 |
| CN118240015B (zh) * | 2024-03-21 | 2025-03-21 | 中国科学院近代物理研究所 | 一种针对脑胶质瘤的靶向多肽及放射性示踪剂 |
| WO2026002208A1 (zh) * | 2024-06-28 | 2026-01-02 | 思路迪生物医药(上海)有限公司 | 前列腺特异性膜抗原小分子抑制剂及其放射性核素配合物的制备及应用 |
| WO2026080432A1 (en) * | 2024-10-07 | 2026-04-16 | Beth Israel Deaconess Medical Center, Inc. | Dimeric p-selectin inhibitors and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5021556A (en) | 1987-07-22 | 1991-06-04 | Neorx Corporation | Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides |
| US5075099A (en) | 1988-05-31 | 1991-12-24 | Neorx Corporation | Metal radionuclide chelating compounds for improved chelation kinetics |
| US5364613A (en) | 1989-04-07 | 1994-11-15 | Sieving Paul F | Polychelants containing macrocyclic chelant moieties |
| US5367080A (en) | 1990-11-08 | 1994-11-22 | Sterling Winthrop Inc. | Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods |
| US5886142A (en) | 1997-05-20 | 1999-03-23 | Thomas Jefferson University | Radiolabeled thrombus imaging agents |
| CA2721183C (en) * | 2008-04-11 | 2019-07-16 | Alnylam Pharmaceuticals, Inc. | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
| EP3609541A4 (en) * | 2017-04-05 | 2021-04-07 | Cornell University | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies |
| CA3060143A1 (en) * | 2017-05-24 | 2018-11-29 | Itm Isotopen Technologien Munchen Ag | Novel psma-binding agents and uses thereof |
| AU2022397307A1 (en) | 2021-11-26 | 2024-06-06 | Full-Life Technologies Uk Limited | Cleavable radioligands for targeting cell surface receptors and uses thereof |
-
2022
- 2022-11-23 AU AU2022397307A patent/AU2022397307A1/en active Pending
- 2022-11-23 JP JP2024531425A patent/JP2024542592A/ja active Pending
- 2022-11-23 KR KR1020247021297A patent/KR20240121775A/ko active Pending
- 2022-11-23 EP EP22899414.1A patent/EP4436979A1/en active Pending
- 2022-11-23 CA CA3238734A patent/CA3238734A1/en active Pending
- 2022-11-23 WO PCT/US2022/050952 patent/WO2023097038A1/en not_active Ceased
- 2022-11-23 CN CN202280078538.7A patent/CN118451091A/zh active Pending
- 2022-11-23 MX MX2024005950A patent/MX2024005950A/es unknown
-
2024
- 2024-03-13 US US18/604,400 patent/US12214059B2/en active Active
- 2024-05-23 CL CL2024001560A patent/CL2024001560A1/es unknown
- 2024-12-03 US US18/967,265 patent/US20250099632A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022397307A1 (en) | 2024-06-06 |
| JP2024542592A (ja) | 2024-11-15 |
| CN118451091A (zh) | 2024-08-06 |
| US20250099632A1 (en) | 2025-03-27 |
| EP4436979A1 (en) | 2024-10-02 |
| KR20240121775A (ko) | 2024-08-09 |
| CA3238734A1 (en) | 2023-06-01 |
| US20240382630A1 (en) | 2024-11-21 |
| MX2024005950A (es) | 2024-08-06 |
| WO2023097038A1 (en) | 2023-06-01 |
| US12214059B2 (en) | 2025-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024001560A1 (es) | Radioligandos escindibles para dirigirse a receptores de la superficie celular y usos de los mismos. | |
| CL2021002883A1 (es) | Moduladores de thr-ß y métodos de uso de estos | |
| MX2021015221A (es) | Compuestos de aminobenzazepina, inmunoconjugados y usos de estos. | |
| PE20252338A1 (es) | Compuesto agonista de receptor thrb y metodo de preparacion | |
| MX2022004875A (es) | Inmunoconjugados de tienoazepina, inmunoconjugados y usos de estos. | |
| AR079205A1 (es) | Morfolinotiazoles como moduladores alostericos positivos alfa 7 | |
| BR112018077362A2 (pt) | conjugados para edição de superfície de célula-alvo | |
| UY30387A1 (es) | Nuevos compuestos | |
| UY37728A (es) | Nuevos enlazantes peptídicos y conjugados de criptoficina, su preparación y su uso terapéutico | |
| CL2023002578A1 (es) | Derivados de alfa-d-galatopiranosido triazolil-metil sustituidos | |
| CL2023002322A1 (es) | Derivados de hidroxiheterocicloalquil-carbamoilo | |
| MX2023006799A (es) | Inmunoconjugados anti-cea y usos de estos. | |
| MX2019007670A (es) | Nuevos antioxidantes para cosmeticos y composiciones farmaceuticas que contienen eteres alquilicos de glicerol. | |
| CO2024010726A2 (es) | Compuestos heterocíclicos y métodos de uso | |
| AR056025A1 (es) | Compuestos de imidazol sustituidos como inhibidores de ksp | |
| DOP2025000090A (es) | Métodos de tratamiento del cáncer usando derivados de isoquinolina o 6-aza-quinolina | |
| CO2022006645A2 (es) | Derivados de 1,2,4–oxadiazol como agonistas del receptor hepático x | |
| PE20250457A1 (es) | Compuestos antivirales y metodos de elaboracion y uso de los mismos | |
| DOP2022000073A (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 | |
| CL2022000892A1 (es) | Derivados de 2–azaespiro[3.4]octano como agonistas de m4 | |
| AR053678A1 (es) | Compuestos farmaceuticamente activos, su manufactura, composiciones que los contienen y su uso | |
| DOP2025000235A (es) | Nuevo compuesto, y una composición farmacéutica para la prevención o el tratamiento del cáncer o tumores que comprende el mismo | |
| AR122407A1 (es) | Composiciones y métodos para tratar la inflamación intestinal usando un inhibidor de ccr9 y anticuerpos de bloqueo anti-il-23 | |
| MX2022009753A (es) | Composiciones y metodos para el tratamiento de la enfermedad de pompe. | |
| MX2025013595A (es) | Degradadores bifuncionales y usos de los mismos |